Paid Clinical Trials Lakeland
Discover 1,744 paid clinical trials in Lakeland, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Mezigdomide & CarfilzomibA Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT05552976
Conditions
Relapsed or Refractory Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Mezigdomide
Carfilzomib
Dexamethasone
CenerimodA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Sponsor:
Idorsia Pharmaceuticals Ltd.
Location:
Code:
NCT05672576
Conditions
Lupus Erythematosus, Systemic
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Cenerimod
Placebo
LY3541860A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT06859294
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
LY3541860
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
Optimizing TreatmentOptimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
Sponsor:
HELP for NOWS Consortium
Location:
Code:
NCT05980260
Conditions
Neonatal Opiate Withdrawal Syndrome
Eligibility Criteria
Sex: All
Age: 1 - 48
Healthy Volunteers: Not accepted
Interventions
Symptom-based Dosing Approach
Scheduled Opioid Taper Approach
LuspaterceptA Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Sponsor:
Celgene
Location:
Code:
NCT04064060
Conditions
Myelodysplastic Syndromes (MDS)
Beta-thalassemia
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Luspatercept
DexamethasonePerivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT
Sponsor:
Mercator MedSystems, Inc.
Location:
Code:
NCT04858776
Conditions
Iliofemoral; Thrombosis
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Perivascular dexamethasone
Perivascular sham
BelumosudilBelumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
Sponsor:
Fred Hutchinson Cancer Center
Location:
Code:
NCT05996627
Conditions
Chronic Graft Versus Host Disease
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Belumosudil
Biospecimen Collection
Electronic Health Record Review
Placebo Administration
Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Sponsor:
Allogene Therapeutics
Location:
Code:
NCT06500273
Conditions
Large B-cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cemacabtagene ansegedleucel
ALLO-647
Fludarabine
Cyclophosphamide
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
AP-CD/LDA Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004
Sponsor:
Intec Pharma Ltd.
Location:
Code:
NCT02615873
Conditions
Parkinson's Disease
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Accordion Pill™ Carbidopa/Levodopa